30th week of 2015 patent applcation highlights part 8 |
Patent application number | Title | Published |
20150202244 | PHARMACEUTICAL COMPOSITION CONTAINING COMPLEX EXTRACT OF AURANTII NOBILIS PERICARPIUM AND CRATAEGUS AS AN ACTIVE INGREDIENT FOR TREATING OR PREVENTING OBESITY OR LIPID-RELATED METABOLIC DISEASES - The present invention provides a pharmaceutical or health functional food containing, as an active ingredient, a complex extract of | 2015-07-23 |
20150202245 | NOVEL BIOACTIVE COMPOUND OBTAINED FROM OIL PALM BASE MATERIALS - This disclosure is directed to a novel bioactive compound obtained from oil palm based materials and compositions containing said bioactive compound. The bioactive compound obtained in accordance with the present invention has a molecular mass of 482. The bioactive compound also has potent HIV reverse transcriptase activity and antioxidant activity. | 2015-07-23 |
20150202246 | COMPOSITIONS FOR TREATMENT OF CANCER-RELATED FATIGUE - Disclosed are compositions containing extracts of (a) | 2015-07-23 |
20150202247 | LOW FREQUENCY GLATIRAMER ACETATE THERAPY - A method of alleviating a symptom of relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis comprising administering to the human patient three subcutaneous injections of a therapeutically effective dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection so as to thereby alleviate the symptom of the patient. | 2015-07-23 |
20150202248 | E2F AS A TARGET OF HORMONE REFRACTORY PROSTATE CANCER - The instant invention provides amino acid sequences competing with E2F for DNA binding. Methods of using said amino acid sequences for treatment of hormone-refractory prostate cancer are also provided. | 2015-07-23 |
20150202249 | ANTI-ANDROGEN PEPTIDES AND USES THEREOF IN CANCER THERAPY - The present invention relates to isolated or purified or partially purified peptide derived molecules having the following general formula (S1): X-[(Pro)n-His-Pro-His-Ala-Arg-Ile-Lys] | 2015-07-23 |
20150202250 | ANTICANCER TREATMENT - Use of fusion protein comprising at least one polypeptide B, comprising Type 1 Ribosome Inactivating Protein, and at least one C having anticancer properties in the manufacture of a medicament for treating cancer in a subject in need thereof. | 2015-07-23 |
20150202251 | MULTIMERIC TIE 2 AGONISTS AND USES THEREOF IN STIMULATING ANGIOGENESIS - The present invention provides a multimeric form of a Tie 2 binding peptide monomer, wherein the multimeric form has Tie 2 agonist activity. The multimeric form, preferably a tetramer, stimulates angiogenesis and promotes wound healing. The present invention also features pharmaceutical compositions comprising the multimeric Tie 2 agonists, including those suitable for topical or systemic administration. Methods of using the multimeric Tie 2 agonists of the invention for stimulating angiogenesis and for promoting healing of wounds, such as diabetic ulcers or skin grafts, are also provided. | 2015-07-23 |
20150202252 | TREATMENT OF ISCHEMIA - A system, including methods and compositions, for treatment of ischemia. | 2015-07-23 |
20150202253 | MODEL SYSTEMS AND TREATMENT REGIMES FOR TREATMENT OF NEUROLOGICAL DISEASE - The invention provides animal models and clinical trials for assessing agents for potential use in treating and effecting prophylaxis stroke and other neurological diseases, particularly those mediated at least in part by excitoxitity. The invention also provides preferred dosage and infusion regimes and pharmaceutical compositions for clinical application of such agents. | 2015-07-23 |
20150202254 | METHOD FOR REDUCING RADIO-RESISTANCE OF PROSTATE CANCER CELLS AND/OR TREATING PROSTATE CANCER - A method for reducing the radio-resistance of prostate cancer cells in a subject in need thereof, comprising administering to the subject an effective amount of an active component, wherein the active component is a nanoparticle of a carrier encapsulated with cytolethal distending toxin subunit B (CdtB). | 2015-07-23 |
20150202255 | TREATMENT AND DIAGNOSIS OF INFLAMMATORY DISORDERS AND HIV - This invention concerns compositions and methods of treating or diagnosing inflammatory disorders and other disorders, as well as compositions and methods of treating HIV. | 2015-07-23 |
20150202256 | DIFFERENTIATION MARKER AND DIFFERENTIATION CONTROL OF EYE CELL - The present invention relates to a differentiation marker and a differentiation controlling technique for an eye cell. More particularly, the present invention has attained an object of providing a differentiation marker for an eye cell among the aforementioned problems, by providing a marker for identifying a cell having a high proliferation ability among corneal endothelial cells and/or the differentiation ability of a corneal endothelial cell, the marker comprising GPR49/LGR5, as well as a detection agent or detection method for identifying a cell having a high proliferation ability among corneal endothelial cells and/or the differentiation ability of a corneal endothelial cell, comprising a substance binding to GPR49/LGR5. In addition, the present invention has attained an object of providing a differentiation controlling technique for an eye cell, by providing an agent for suppressing differentiation and/or promoting proliferation of an eye cell, comprising R-spondins. | 2015-07-23 |
20150202257 | METHODS AND COMPOSITIONS FOR METABOLIC REGULATION - The invention relates, in part, to methods and compositions that are useful to modulate metabolic function of cells in vivo or in vitro. In some aspects the invention includes methods and/or compositions that increase metabolism in cells, tissues, organs, and/or subjects. In certain aspects the invention includes methods and/or compositions useful to decrease metabolism in cells, tissues, organs, and/or in subjects. | 2015-07-23 |
20150202258 | Medicament for wound treatment - The invention relates to stathmin, stathmin, a nucleic acid encoding said stathmin or a cell expressing stathmin for use in the treatment of chronic wounds or disease- or medication-dependent impaired wound healing in a patient or for increasing or inducing the proliferation and/or migration of mesenchymal cells, of stem cells, for stimulating immune cells, preferably natural killer cells, for stimulating fibroblasts, for stimulating epithelial cells, preferably epithelial cells of the epidermis, or for stimulating angiogenesis. | 2015-07-23 |
20150202259 | TARGETED OESOPHAGEAL ADMINISTRATION OF ZN-ALPHA2-GLYCOPROTEINS (ZAG), METHODS AND FORMULATIONS THEREOF - The invention provides formulations and methods for ameliorating symptoms associated with metabolic disorders, such as hypoglycemia, obesity, diabetes, and the like by targeted administration to the oesphagus of a subject of Zn-α | 2015-07-23 |
20150202260 | ENDOGLIN PEPTIDES TO TREAT FIBROTIC DISEASES - In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a truncated, ligand-binding portion of the extracellular domain of endoglin (ENG) polypeptide may be used to treat fibrotic disorders. | 2015-07-23 |
20150202261 | METHODS AND COMPOSITIONS FOR TREATING ANTIPROGESTIN-RESISTANT CANCERS - The invention provides methods, pharmaceutical compositions and kits for treating a subject having a carcinoma that is resistant to an antiprogestin. In particular, the methods comprise increasing the molar amount of progesterone receptor isoform A (PR-A) so that it is greater than that of isoform B (PR-B) and administering a therapeutically effective amount of an antiprogestin to the subject, thereby treating the carcinoma. | 2015-07-23 |
20150202262 | TREATMENT OF ALLODYNIA, HYPERALGESIA, SPONTANEOUS PAIN AND PHANTOM PAIN - The present invention relates to the use of Meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain. In a preferred embodiment the disorder to be treated is allodynia, and hyperalgesia, more preferably allodynia including thermal and tactile allodynia. | 2015-07-23 |
20150202263 | NEURTURIN MOLECULES - Neurturin polypeptides which possess reduced heparin and heparan sulfate binding affinity but retain neurotrophic activity, nucleic acids which encode the neurturin variants and vectors and host cells which express the enhanced neurturin polypeptides. Use of the enhanced neurturin polypeptides, nucleic acids and host cells in the treatment or prevention of disease. | 2015-07-23 |
20150202264 | PLATELET ACTIVATION AND GROWTH FACTOR RELEASE USING ELECTRIC PULSES - Methods and systems for releasing growth factors are disclosed. In certain embodiments, a blood sample is exposed to a sequence of one or more electric pulses to trigger release of a growth factor in the sample. In certain embodiments, the growth factor release is not accompanied by clotting within the blood sample. | 2015-07-23 |
20150202265 | METHOD FOR PREPARING A BONE PROTEIN PREPARATION AND A BONE PROTEIN PREPARATION - The present invention provides a method for preparing a bone protein preparation which contains for example growth factors. The present invention also provides a bone protein preparation obtained by the method and paste, putty, pellet, disc, block, granule, osteogenic device or pharmaceutical composition containing said bone protein preparation. | 2015-07-23 |
20150202266 | COMPOSITION AND METHOD FOR REDUCING TISSUE DAMAGE FROM INFLAMMATORY DISORDER OR PATHOGENIC INFECTION - Compositions and methods for preventing or ameliorating tissue damage caused by an inflammatory disorder or pathogenic infections are described. In one aspect, a method for preventing or ameliorating tissue damage caused by an inflammatory disorder or pathogenic infection comprises administering to a subject a therapeutically effective amount of a neuregulin. In another aspect, the composition comprises one or more active agents that: (a) increase expression or activity of a neuregulin; (b) inhibit the expression or activity of CXCL10, STAT3 or HEME; or (c) both (a) and (b). | 2015-07-23 |
20150202267 | USE OF INTERLEUKIN-22 IN TREATING VIRAL HEPATITIS - This invention relates to a use of IL-22 in the treatment of viral hepatitis. As illustrated in the examples of this invention, IL-22 can significantly reduce liver damage caused by hepatitis virus, and can significantly reduce the increase of transaminase ALT/AST induced by heptatitis virus. In addition, the IL-22 dimer of this invention can effectively treat viral hepatitis. | 2015-07-23 |
20150202268 | Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor for the Prevention of Neutropenia - Disclosed are compositions and methods for treating, preventing and ameliorating conditions and diseases characterized by a lowered white blood cell count. The methods and compositions described herein include a fusion polypeptide formed from human serum albumin protein (“HSA”) and human granulocyte-colony stimulating factor (“G-CSF”). | 2015-07-23 |
20150202269 | AAV-MEDIATED GENE THERAPY FOR RPGR X-LINKED RETINAL DEGENERATION - Described herein are methods of preventing, arresting progression of or ameliorating vision loss and other conditions associated with retinitis pigmentosa and x-linked retinitis pigmentosa in a subject. The methods include administering to said subject an effective concentration of a composition comprising a recombinant adeno-associated virus (AAV) carrying a nucleic acid sequence encoding a normal retinitis pigmentosa GTPase regulator (RPGR gene), or fragment thereof, under the control of regulatory sequences which express the product of the gene in the photoreceptor cells of the subject, and a pharmaceutically acceptable carrier. | 2015-07-23 |
20150202270 | METHODS FOR INTRODUCING MANNOSE 6 PHOSPHATE AND OTHER OLIGOSACCHARIDES ONTO GLYCOPROTEINS AND APPLICATIONS THEREOF - Methods to introduce highly phosphorylated mannopyranosyl oligosaccharide derivatives containing mannose-6-phosphate (MSP), or other oligosaccharides bearing other terminal hexoses, to carbonyl groups on oxidized glycans of glycoproteins while retaining their biological activity are described. The methods are useful for modifying glycoproteins, including those produced by recombinant protein expression systems, to increase uptake by cell surface receptor-mediated mechanisms, thus improving their therapeutic efficacy in a variety of applications. | 2015-07-23 |
20150202271 | DNA VACCINE CONTAINING VEGF-SPECIFIC EPITOPE AND/OR ANGIOPOIETIN-2-SPECIFIC EPITOPE - The present invention provides a therapeutic or prophylactic agent for cancer, containing an expression vector encoding a chimeric Hepatitis B virus core antigen polypeptide inserted with an amino acid sequence containing a specific epitope of VEGF and/or a specific epitope of angiopoietin-2, wherein the amino acid sequence containing the specific epitope is inserted between the amino acid residues 80 and 81 of the hepatitis B virus core antigen polypeptide. | 2015-07-23 |
20150202272 | METHODS AND COMPOSITIONS FOR ENHANCING VACCINE IMMUNE RESPONSES - Provided herein are immunogenic compositions comprising a recombinant modified vaccinia virus Ankara (MVA) comprising a nucleic acid sequence encoding a CD40 ligand (CD40L) and a nucleic acid sequence encoding a heterologous disease-associated antigen, wherein the immunogenic composition induces increases T-cell immune responses specific for the heterologous disease-associated antigen when administered to a human host, and related methods and uses. | 2015-07-23 |
20150202273 | PROSTATE-SPECIFIC TUMOR ANTIGENS AND USES THEREOF - Twenty-one PSGR-derived peptides predicted by an immuno-informatics approach based on the HLA-A2 binding motif were examined for their ability to induce peptide-specific T cell responses in peripheral blood mononuclear cells (PBMCs) obtained from either HLA-A2+ healthy donors or HLA-A2+ prostate cancer patients. The recognition of HLA-A2 positive and PSGR expressing LNCaP cells was also tested. Three peptides, PSGR3, PSGR4 and PSGR14 frequently induced peptide-specific T cell responses in PBMCs from both healthy donors and prostate cancer patients, and are recognized by CD8+ T cells in an HLA-A2 dependent manner. These peptide-specific T cells recognize HLA-A2+ and PSGR+ tumor cells, and killed LNCaP prostate cancer cells in an HLA class I-restricted manner. These PSGR-derived peptides identified are useful as diagnostic markers as well as immune targets for anticancer vaccines. | 2015-07-23 |
20150202274 | PURIFICATION OF BACTERIAL VESICLES - A two stage filtration process is used to purify immunogenic bacterial vesicles. A first step separates the vesicles from intact bacteria based on their different sizes, with the smaller vesicles passing into the filtrate (permeate). A second step then uses a finer filter to remove smaller contaminants, with the vesicles remaining in the retentate. This two stage process is extremely simple to operate but has been shown to give vesicles of high purity. | 2015-07-23 |
20150202275 | PLAGUE VACCINE - The application relates to a | 2015-07-23 |
20150202276 | METHODS FOR PRODUCING AN IMMUNE RESPONSE TO TUBERCULOSIS - Methods for producing an immune response to | 2015-07-23 |
20150202277 | STABILISED PROTEINS FOR IMMUNISING AGAINST STAPHYLOCOCCUS AUREUS - Elimination of disulphide bond formation of cysteine-containing | 2015-07-23 |
20150202278 | Method of Using Attenuated Bordetella Strains | 2015-07-23 |
20150202279 | ANTIGENS AND ANTIGEN COMBINATIONS - NTHI protein antigens have been identified and found to be conserved across several | 2015-07-23 |
20150202280 | Mutant Forms of Chlamydia HtrA - An immunogenic | 2015-07-23 |
20150202281 | Molecular Antigen Array - The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses. | 2015-07-23 |
20150202282 | PCV2 ORF2 VIRUS LIKE PARTICLE WITH FOREIGN AMINO ACID INSERTION - The present invention comprises methods and compositions related to the production and use of amino acid sequences. In particular, PCV2 ORF2 is shown to be useful as a virus-like particle which produces amino acid sequences that retain their immunogenicity or antigenicity when the DNA encoding the PCV2 ORF2 is inserted into an expression system. DNA sequences that are foreign to PCV2 can be attached “in-frame” to the ORF2 DNA and the entire sequence, including the DNA foreign to PCV2, is expressed. It was shown that such sequences retain their antigenicity and therefore their potential utility in immunogenic compositions. | 2015-07-23 |
20150202283 | METHOD FOR ELICITING IN INFANTS AN IMMUNE RESPONSE AGAINST RSV AND B. PERTUSSIS - This disclosure provides methods for protecting infants against disease caused by respiratory syncytial virus (RSV) and | 2015-07-23 |
20150202284 | METHOD OF MAKING A VACCINE - The present invention provides a vaccine and method for making same which is effective to elicit a desired antibody against a target antigen comprising a primary immunogen and a secondary immunogen, wherein the primary immunogen is effective to elicit B cell receptors (BCRs) that are on the maturational pathway of the desired antibody and have an intermediate degree of somatic mutational diversity, and the secondary immunogen comprises an epitope of the desired target antibody and is effective to further diversify the BCRs sufficient to form mature BCRs having the identical or substantially identical sequence as the desired antibody. | 2015-07-23 |
20150202285 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES - This invention discloses methods and compositions for modulating immune responses, which involve particulate delivery of agents to immune cells, wherein the agents comprise an inhibitor of the NF-κB signaling pathway and an antigen that corresponds to a target antigen. The methods and compositions of the present invention are particularly useful in the treatment or prophylaxis of an undesirable immune response associated with the target antigen, including autoimmune diseases, allergies and transplantation associated diseases. | 2015-07-23 |
20150202286 | Toxicity Management for Anti-Tumor Activity of CARs - The present invention provides compositions and methods for treating cancer in a patient. In one embodiment, the method comprises a first-line therapy comprising administering to a patient in need thereof a genetically modified T cell expressing a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain and monitoring the levels of cytokines in the patient post T cell infusion to determine the type of second-line of therapy appropriate for treating the patient as a consequence of the presence of the CAR T cell in the patient. | 2015-07-23 |
20150202287 | COMBINATION THERAPIES COMPRISING ANTI-ERBB3 AGENTS - Disclosed are methods and compositions for inhibiting the growth of a tumor (e.g., a malignant 5 tumor) in a subject. In particular, combination therapies for treating a tumor in a subject by coadministering an agent selected from i) an effective amount of an anti-estrogen agent; ii) an effective amount of a receptor tyrosine kinase inhibitor; iii) an effective amount of a MEK/PI3 kinase/AKT inhibitor; iv) an effective amount of MM-151; v) an effective amount of an mTOR inhibitor; and/or vi) an effective amount of trastuzumab or T-DM 1, and/or combinations thereof; and an effective amount of a 10 bispecific anti-ErbB2/anti-ErbB3 antibody. | 2015-07-23 |
20150202288 | Combination Therapy for the Treatment of Ocular Neovascular Disorders - The invention features methods for treating a patient diagnosed with, or at risk of developing, a neovascular disorder by administering a PDGF antagonist and a VEGF antagonist to the patient. The invention also features a pharmaceutical composition containing a PDGF antagonist and a VEGF antagonist for the treatment or prevention of a neovascular disorder. | 2015-07-23 |
20150202289 | COMBINATION THERAPY FOR THE TREATMENT OF OCULAR NEOVASCULAR DISORDERS - The invention features methods for treating a patient diagnosed with, or at risk of developing, a neovascular disorder by administering a PDGF antagonist and a VEGF antagonist to the patient. The invention also features a pharmaceutical composition containing a PDGF antagonist and a VEGF antagonist for the treatment or prevention of a neovascular disorder. | 2015-07-23 |
20150202290 | METHOD FOR TREATING MELANOMA USING A HERPES SIMPLEX VIRUS AND AN IMMUNE CHECKPOINT INHIBITOR - The invention relates to methods of treating melanoma using a herpes simplex virus in combination with an immune checkpoint inhibitor. | 2015-07-23 |
20150202291 | COMBINATIONS OF CHECKPOINT INHIBITORS AND THERAPEUTICS TO TREAT CANCER - A combination treatment regimen including one or more cycles and/or doses of a checkpoint inhibitor and a therapeutic, either sequentially, in either order, or substantially simultaneously, can be more effective in treating cancer in some subjects and/or can initiate, enable, increase, enhance or prolong the activity and/or number of immune cells, the efficacy of anti-tumor immune responses or a medically beneficial response by a tumor. | 2015-07-23 |
20150202292 | ELECTROCHEMICALLY DEGRADABLE POLYMERS - The present invention discloses polymeric materials that incorporate a modified quinone moiety, either to cross-link the polymer or as a monomeric unit of the polymer These polymeric materials can be efficiently degraded through electrochemical reduction of the quinone leading to rapid hydrolysis of the pendant chemical groups and degradation of the polymer. Quinone-containing compositions and methods of producing electrochemically degradable polymers are disclosed. The methods and compositions of the present invention can be used in a wide variety of applications, including, but not limited to, drug delivery, tissue regeneration, biomedical implants, and electronic systems. | 2015-07-23 |
20150202293 | CONJUGATE OF A PHOTOSENSITISER AND CHITOSAN AND USES THEREOF - The present invention relates to novel chitosan-based conjugates, e.g. nanocarriers, comprising a derivative of the biocompatible polymer chitosan conjugated to a photosensitising agent, and uses thereof in photochemical internalisation (PCI) and photodynamic therapy (PDT). The invention also relates to the use of the novel conjugates of the invention in treatment or prevention of diseases, particularly cancer, and for vaccination purposes. | 2015-07-23 |
20150202294 | USE OF PSORALEN DERIVATIVES AND COMBINATION THERAPY FOR TREATMENT OF CELL PROLIFERATION DISORDERS - Methods for the treatment of a cell proliferation disease or disorder in a subject, involving applying a psoralen derivative lacking a DNA cross-linking motif to cancer cells, applying a psoralen or a derivative thereof and lapatinib, or applying a psoralen or derivative thereof and neratinib, to a subject and further applying initiation radiation energy form an energy source. | 2015-07-23 |
20150202295 | HYBRID HYDROGELS - The present invention relates to compositions and pharmaceutical compositions forming hydrogels, their use in medical applications and methods of making same as well as medical devices comprising same. | 2015-07-23 |
20150202296 | METHOD FOR ADMINISTERING GLP-1 MOLECULES - The invention relates to formulations that demonstrate the feasibility of oral absorption comprising glucose-like peptide-1 compounds and specified delivery agents, and to methods of stimulating GLP-1 receptor in a subject in need of such stimulation, by administration of the formulation of the present invention. | 2015-07-23 |
20150202297 | DRY POWDER INHALERS COMPRISING A CARRIER OTHER THAN LACTOSE AND A TERNARY COMPONENT - This invention relates to novel pharmaceutical compositions for inhalation comprising separately, sequentially or together, drugs having amine in the form of a dry powder in admixture with a pharmaceutically acceptable carrier, other than lactose, and its use in the treatment of respiratory condition selected from asthma and chronic obstructive pulmonary disease (COPD) and other obstructive airways diseases. More particularly, the invention relates to pharmaceutical composition for inhalation further comprising a ternary component. In addition, the present invention relates to novel pharmaceutical composition for inhalation based on combinations of long acting muscarinic antagonists, long acting beta agonists, short acting beta-2 agonists, corticosteroids or a combination of two or more of them. | 2015-07-23 |
20150202298 | Compositions for Targeted Delivery of siRNA - The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted delivery polymers. Delivery polymers provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery polymers. | 2015-07-23 |
20150202299 | STABILIZING SHEAR-THINNING HYDROGELS - The present inventions are directed to shear-thinning and stabilizing hydrogels, especially for use in drug delivery and therapy. Various embodiments provide settable, shear-thinning hydrogels, each hydrogel comprising a hydrophilic polymer network, said hydrophilic polymer network comprising non-covalent crosslinks and at least one set of chemical moieties being capable of participating in at least one chemical covalent cross-linking reaction. In certain embodiments, these settable shear-thinning hydrogels are triggerable to cross-link by the application of a stimulus. | 2015-07-23 |
20150202300 | Tamper Resistant Pharmaceutical Formulations - Disclosed in certain embodiments is a solid oral dosage form comprising a heat-labile gelling agent; a thermal stabilizer; and a drug susceptible to abuse. | 2015-07-23 |
20150202301 | NOVEL ESTERIFIED CELLULOSE ETHERS OF HIGH MOLECULAR WEIGHT AND HOMOGENEITY - Esterified cellulose ethers which have i) a combination of aliphatic monovalent acyl groups and groups of the formula —C(O)—R—COOA wherein R is a divalent aliphatic or aromatic hydrocarbon group and A is hydrogen or a cation, ii) a weight average molecular weight Mw of from 80,000 Dalton to 350,000 Dalton, iii) a Polydispersity Mw/Mn of from 1.3 to 4.1, and iv) a viscosity of up to 4.0 mPa s, measured as a 2.0 wt % solution of the esterified cellulose ether in 0.43 wt % aqueous NaOH at 20° C., are useful as enteric polymers for pharmaceutical dosage forms. | 2015-07-23 |
20150202302 | MODIFIED RELEASE FORMULATIONS OF PRIDOPIDINE - The subject invention provides a modified release solid oral dosage form comprising a therapeutically effective amount of Pridopidine or as pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable rate controlling excipient, wherein the solid oral dosage form provides an in vivo plasma pridopidine concentration profile having a Mean C | 2015-07-23 |
20150202303 | 2-IMINOBIOTIN FORMULATIONS AND USES THEREOF - The disclosure relates to improving the aqueous solubility of 2-iminobiotin. In a particular aspect, the disclosure pertains to formulations suitable for administration of 2-iminobiotin to mammals suffering from disorders or conditions that benefit from that administration. | 2015-07-23 |
20150202304 | ENCAPSULATION OF IMMISCIBLE PHASES IN SILK FIBROIN BIOMATERIALS - Embodiments of various aspects described herein relates to compositions and methods for encapsulation and/or stabilization of oil, lipid, hydrophobic and/or lipophilic compounds in a silk-based material. The compositions described herein can be used in various applications, e.g., pharmaceutical, cosmetic, food, diagnostic, and tissue engineering applications. | 2015-07-23 |
20150202305 | METHOD OF CREATING HYDROGELS THROUGH OXIME BOND FOMRATION - A method of creating a hydrogel, comprising the step of condensing first and second functional groups, wherein the first group comprises a molecule or macromolecule of interest containing two or more hydroxylamine or aminooxy groups and the second group comprises a molecule or macromolecule of interest containing two or more aldehyde/ketone/other reactive oxo groups, under conditions such that a hydrogel forms. | 2015-07-23 |
20150202306 | OPHTHALMIC COMPOSITIONS WITH WAX ESTERS - A suspension comprising a mixture of wax esters suspended in a formulation vehicle. The formulation vehicle comprises a lightly cross-linked carboxy-containing polymer and a concentration of ionic salt components to provide the suspension with a calculated ionic strength of less than 0.1. The suspension has the following rheological properties, (T>G″ and a suspension yield value of greater than 1 Pa. Also, upon addition of 30 mL of the suspension to a volume of 6 mL to 12 mL of simulated tear fluid, the resulting tear mixture transitions to a liquid form wherein, G″>G′ and the tear mixture has a yield value of less than 0.1 Pa. | 2015-07-23 |
20150202307 | Colloid Bonded Medicinal Compounds - The invention relates to colloids bound medicinal compounds or fluorescent markers, to a process for the preparation thereof, and to a pharmaceutical formulation containing such compounds. | 2015-07-23 |
20150202308 | BUDESONIDE FORMULATION - The invention provides budesonide inhalation formulations containing cyclodextrins. | 2015-07-23 |
20150202309 | Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens and Uses Thereof - The present invention relates to new immunogenic compositions comprising conjugated | 2015-07-23 |
20150202310 | ALBUMIN BINDING PROBES AND DRUG CONJUGATES THEREOF - The present invention provides a long chain fatty acid (LCFA)-like albumin-binding probe/ligand containing no hydrolysable bond and having an enhanced associating affinity with human serum albumin, which upon conjugation with an amino- or mercapto-containing short-lived drug and administration of the conjugate, significantly prolongs the life time of said drug without substantially interfering with its pharmacological activity. The invention further provides conjugates of said probe with amino- or mercapto-containing drugs, as well as pharmaceutical compositions and uses thereof. | 2015-07-23 |
20150202311 | Collagen-peptide complex - [Theme] An object is to provide a collagen-containing composition for oral ingestion wherein the resulting peptide-type Hyp is effectively transferred into the blood. | 2015-07-23 |
20150202312 | INTERFERON-ALPHA FUSION PROTEIN IN WHICH CYTOPLASMIC TRANSDUCTION PEPTIDE AND POLYETHYLENE GLYCOL ARE BONDED TO ONE ANOTHER - The present invention relates to IFN-α fusion protein in which a cytoplasmic transduction peptide (CTP) and polyethylene glycol (PEG) are bonded to an IFN-α protein. The IFN-α fusion protein of the present invention is characterized in that the specific activity of interferon remains high, the half-life of the INF-α fusion protein is extended when delivered in vivo, and the mobility of the interferon in a liver is improved. The IFN-α fusion protein of the present invention can be used in the development of protein drugs effective in preventing or treating liver diseases, including various types of viral infections or the like. | 2015-07-23 |
20150202313 | Macromolecular Prodrugs for Hard Tissue and Methods of Use Thereof - Methods and compositions for treating bone disorders are disclosed. | 2015-07-23 |
20150202314 | SITE-SPECIFIC LABELING AND TARGETED DELIVERY OF PROTEINS FOR THE TREATMENT OF CANCER - The present invention relates to the formation of protein conjugates from proteins chemically modified for linkage to (1) anticancer drug pharmacophores, (2) ligands to biomarkers on cancer cell surfaces, (3) and/or another protein molecule. It provides and specifies new compositions, methods and combinations for tumor, and tumor vasculature targeting and cancer treatment. | 2015-07-23 |
20150202315 | CANCER TARGETING PEPTIDES FOR ENHANCING ANTI-CANCER DRUG DELIVERY AND THERAPEUTIC EFFICENCIES - A peptide targeted conjugate is disclosed. The conjugate comprises: (a) an isolated or a synthetic targeting peptide of less than 15 amino acid residues in length, comprising an amino acid sequence having at least 90% identity to a sequence selected from the group consisting of SEQ ID NOs: 1, 2 and 3; and (b) a component, to which the targeting peptide is conjugated, the component being selected from the group consisting of a drug delivery vehicle, an anti-cancer drug, a micelle, a nanoparticle, liposomes, a polymer, a lipid, an oligonucleotide, a peptide, a polypeptide, a protein, a cell, an imaging agent, and a labeling agent. The conjugate may further comprise an anti-cancer agent encapsulated within the drug delivery vehicle. Compositions and methods of treating cancer are also disclosed. | 2015-07-23 |
20150202316 | LUNG CANCER SPECIFIC PEPTIDES FOR TARGETED DRUG DELIVERY AND MOLECULAR IMAGING - A conjugate is disclosed. The conjugate comprises (a) an isolated or a synthetic targeting peptide of less than 15 amino acid residues in length, comprising an amino acid sequence having at least 90% identity to a sequence selected from the group consisting of SEQ ID NOs: 1-8; and (b) a component conjugated to the targeting peptide, the component being selected from the group consisting of a drug delivery vehicle, an anti-cancer drug, a micelle, a nanoparticle, a liposome, a polymer, a lipid, an oligonucleotide, a peptide, a polypeptide, a protein, a cell, an imaging agent, and a labeling agent. Methods of treating lung cancer and detecting lung cancer cells are also disclosed. | 2015-07-23 |
20150202317 | DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS - The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof, comprising a drug linker conjugate D-L, wherein D being a biologically active moiety containing an aliphatic amine group is conjugated to one or more polymeric carriers via dipeptide-containing linkers L. Such carrier-linked prodrugs achieve drug releases with therapeutically useful half-lives. The invention also relates to pharmaceutical compositions comprising said prodrugs and their use as medicaments. | 2015-07-23 |
20150202318 | ABERRANT CELL-RESTRICTED IMMUNOGLOBULINS PROVIDED WITH A TOXIC MOIETY - Described are immunoglobulins provided with a toxic moiety, comprising at least an immunoglobulin variable region that specifically binds to an MHC-peptide complex preferentially associated with aberrant cells. These immunoglobulins provided with a toxic moiety are preferably used in selectively modulating biological processes. The provided immunoglobulins provided with a toxic moiety are of particular use in pharmaceutical compositions for the treatment of diseases related to cellular aberrancies, such as cancers and autoimmune diseases. | 2015-07-23 |
20150202319 | Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased Toxicity - The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. | 2015-07-23 |
20150202320 | Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased Toxicity - The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. | 2015-07-23 |
20150202321 | COMPOSITIONS COMPRISING CHITOSAN-DRUG CONJUGATES AND METHODS OF MAKING AND USING THE SAME - The present disclosure relates to nanosized chitosan-statin conjugates, nanosized chitosan-chemotherapeutic agent conjugates, compositions comprising such nanosized chitosan-drug conjugates, and methods of making and using the same. The compositions result in unexpected and dramatic improved bioavailability of the component statin or chemotherapeutic agent. | 2015-07-23 |
20150202322 | INTESTINAL PEPTIDE TARGETING LIGANDS - Peptide ligands for transporting therapeutic agents across the intestinal epithelial barrier that ordinarily are inadequately absorbed and must be delivered by alternative means, which contain an isolated amino acid sequence wherein at least one pair of amino acids are of an opposite charge and the pair members are separated by a spacer of 1-12 amino acid residues including at least one hydrophobic amino acid, and wherein the length of the amino acid sequence is greater than 5 and less than 20 amino acids. Pharmaceutical compositions for gastro-intestinal delivery and methods for the gastrointestinal delivery of poorly absorbed therapeutic agents are also disclosed. | 2015-07-23 |
20150202323 | NUCLEIC ACID COMPLEXES - The invention relates to nucleic acid complexes, methods of preparation thereof, and uses thereof for delivering a nucleic acid into a cell. | 2015-07-23 |
20150202324 | ADENOVIRAL VECTORS AND METHODS AND USES RELATED THERETO - The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies. More specifically, the present invention relates to oncolytic adenoviral vectors and cells and pharmaceutical compositions comprising said vectors. The present invention also relates to a use of said vectors in the manufacture of a medicament for treating cancer in a subject and a method of treating cancer in a subject. Furthermore, the present invention relates to methods of producing GM-CSP in a cell and increasing tumor specific immune response in a subject, as well as uses of the oncolytic adenoviral vector of the invention for producing GM-CSF in a cell and increasing tumor specific immune response in a subject. | 2015-07-23 |
20150202325 | ONCOLYTIC VACCINIA VIRUS CANCER THERAPY - Embodiments of the invention are directed methods that include a thymidine kinase deficient vaccinia virus. The methods include administering the vaccinia virus at increased viral concentrations. Further aspects of the invention include methods for inducing oncolysis or collapse of tumor vasculature in a subject having a tumor comprising administering to a subject at least 1×10 | 2015-07-23 |
20150202326 | MULTI-ENCAPSULATED FORMULATIONS MADE WITH OXIDIZED CELLULOSE - A microsphere and method for forming the same are disclosed. The microsphere includes modified cellulose and at least one of a visualization agent, a magnetic material, or a radioactive material. | 2015-07-23 |
20150202327 | MOLECULAR ASSEMBLY USING BRANCHED AMPHIPHILIC BLOCK POLYMER, AND DRUG TRANSPORTATION SYSTEM - The present invention provides a molecular assembly whose retention time in a target site is adjusted depending on the kind or purpose of a labeling agent or drug encapsulated therein, and a molecular assembly that can suppress the ABC phenomenon and that can be administered more than once within a short span. A molecular assembly comprising: a branched-type amphiphilic block polymer A comprising a branched hydrophilic block comprising sarcosine and a hydrophobic block comprising a polylactic acid chain; and a functional substance F comprising a functional site and a polylactic acid chain, wherein the polylactic acid chain constituting the hydrophobic block of the amphiphilic block polymer A comprises L-lactic acid units, and the polylactic acid chain contained in the functional substance F comprises D-lactic acid units, or the polylactic acid chain constituting the hydrophobic block of the amphiphilic block polymer A comprises D-lactic acid units, and the polylactic acid chain contained in the functional substance F comprises L-lactic acid units. | 2015-07-23 |
20150202328 | ARTIFICIAL LIPID-POLYMER-DNA COMPLEX, BIOIMAGING AGENT AND PREPARATION METHOD THEREOF - An artificial lipid-polymer-DNA complex, an in-vivo imaging agent, a pharmaceutical composition and a method of preparing the same are provided. The artificial lipid bilayer includes a polymer matrix including polylactic-co-glycolic acid disposed within a lipid membrane. | 2015-07-23 |
20150202329 | Methods and Composition for Detecting Intestinal Cell-Barrier Dysfunction - Methods for detecting intestinal cell barrier dysfunction in a patient are disclosed. In one method, patient intestinal epithelial cells (IECs), oropharyngeal epithelial cells (OECs) or buccal epithelial cells (BECs) are stained with detectable probes specific against caspase-1 and caspase-3&7, and the cells are viewed for the presence of elevated levels of caspase-1, as evidence by a significantly higher ratio of caspase-1 marker to caspase-3&7, as an indicator of cell barrier dysfunction. In a second method, in situ images of a patient's IEC's, OECs or BECs are obtained by probe-based confocal laser endomicroscopy (pCLE), and images are analyzed for density of cell gaps. Also disclosed is a probe composition for use in detecting intestinal cell barrier dysfunction. | 2015-07-23 |
20150202330 | CONTRAST AGENTS, METHODS FOR PREPARING CONTRAST AGENTS, AND METHODS OF IMAGING - Provided is a protein contrast agent for enhancing an MRI image and comprising a polypeptide having a conformation presenting at least five oxygen atoms positioned to chelate at least one paramagnetic metal ion such as Gd | 2015-07-23 |
20150202331 | Sulfonic Esters of Metal Oxides and Methods of Their Use - The present disclosure is directed to sulfonic esters of metal oxides including those of formulas I and II: | 2015-07-23 |
20150202332 | LABELED MOLECULAR IMAGING AGENTS AND METHODS OF USE - Imaging agents are described that comprise labeled substrates capable of being introduced into cells via the cystine/glutamate antiporter. The substrates may be used for imaging or detecting oxidative stress in cells by introducing the labeled agents into cells via the cystine/glutamate antiporter and subsequent detection. | 2015-07-23 |
20150202333 | LABELED MOLECULAR IMAGING AGENTS AND METHODS OF USE - Imaging agents are described that comprise labeled substrates capable of being introduced into cells via the cystine/glutamate antiporter. The substrates may be used for imaging or detecting oxidative stress in cells by introducing the labeled agents into cells via the cystine/glutamate antiporter and subsequent detection. | 2015-07-23 |
20150202334 | COMPOSITION FOR THERAPEUTIC USE, INCLUDING AN ORGANIC LIPID PHASE AND A RARE-EARTH RADIOISOTOPE COMPLEX - The invention relates to a therapeutic composition including a complex having the following formula (1), including a rare-earth radioisotope in ionic form, said complex being solubilized in an organic lipophilic phase: [M(L) | 2015-07-23 |
20150202335 | TARGETED MOLECULAR IMAGING PROBE AND METHOD FOR IN VIVO MOLECULAR IMAGING - Disclosed is a targeted molecular imaging probe consisting of a signal component, a component with a targeted affinity to Cx43 and a linker. The biochemical variation characteristic of connexin43 (Cx43) associated with cardiovascular diseases (especially arrhythmia) and neoplastic diseases can be reflected in the form of an image by using the targeted molecular imaging probe capable of being detected by an imaging device, to achieve in vivo molecular imaging. | 2015-07-23 |
20150202336 | Loading Technique for Preparing Radionuclide Containing Nanoparticles - The present invention relates to a novel composition and method for loading delivery systems such as liposome compositions with radionuclides useful in targeted diagnostic and/or therapy of target site, such as cancerous tissue and, in general, pathological conditions associated with leaky blood vessels. The composition and methods of the invention find particular use in diagnosing and imaging cancerous tissue and, in general, pathological conditions associated with leaky blood vessels in a subject. The present invention provides a new diagnostic tool for the utilization of positron emission tomography (PET) imaging technique. One specific aspect of the invention is directed to a method of producing nanoparticles with desired targeting properties for diagnostic and/or radio-therapeutic applications. | 2015-07-23 |
20150202337 | IRON GARNET NANOPARTICLES FOR CANCER RADIOTHERAPY AND CHEMOTHERAPY - Iron garnet nanoparticles and or iron garnet particles containing various activatable nuclides, such as holmium-165( | 2015-07-23 |
20150202338 | Method for Processing Tissues - Methods for processing tissue are provided. In some embodiments, the methods comprise methods for decellularizing tissue samples by applying high hydrostatic pressure to the tissues samples. In some embodiments, the methods comprise methods for thawing tissue samples and/or reducing the bioburden in a sample by applying high hydrostatic pressure to the tissue samples. | 2015-07-23 |
20150202339 | DECONTAMINATION SYSTEM INCLUDING ENVIRONMENTAL CONTROL USING A DECONTAMINATING SUBSTANCE - A system for decontaminating a device, such as a medical device, includes a decontamination chamber configured to retain the device and a chemical dispersion assembly configured to deliver a decontaminating fluid to the decontamination chamber. A pressure control assembly is connected to the decontamination chamber and configured to control the pressure in the decontamination chamber. The system also includes a system controller configured to control the decontamination chamber, chemical dispersion assembly, and pressure control assembly. A decontaminating fluid is added into the decontamination chamber at a first rate while increasing the pressure in the decontamination chamber. Adding the decontaminating fluid increases a relative humidity in the decontamination chamber. | 2015-07-23 |
20150202340 | Scent Dispenser System - An scent dispenser housing system for housing an air freshener within a hanging position or a supported position. The scent dispenser housing system generally includes a housing having a base member having a plurality of base vents and a cover member having a plurality of cover vents removably connected to the base member to form an interior cavity that receives a fragrance dispenser. A connecting member is removably connected to the housing to allow the housing to be hung from an object when attached to the housing or removed to allow for the housing to be positioned upon a support surface such as a table. | 2015-07-23 |
20150202341 | PHOTO CATALYTIC AIR PURIFIER - An air purification system includes a housing having an inlet and a panel. The panel at least partially defines a volume for receiving air from the inlet. The system also includes an internal support structure coupled to the housing and configured to support a plurality of components of the air purifier. The system further includes a blower configured to drive air through the air purifier components. The system also includes a first drawer including a mesh screen having a photocatalytic oxidation catalyst disposed on its surface. The first mesh screen is placed within the flow of air. The system further includes a second drawer including an ultraviolet light bulb in line-of-site position relative to the mesh screen. The system also includes a light shield configured to eliminate line-of-site access to the ultraviolet light bulb from an outlet of the air purification system. | 2015-07-23 |
20150202342 | HAEMOSTATIC PATCH AND METHOD OF PREPARATION - The present invention relates to a haemostatic patch comprising a porous layer based on oxidized cellulose and a neutralized film based on chitosan, said film comprising a free face and a face fixed on one of the faces of the porous layer, and to the method of preparing said patch comprising the following steps:—a°) preparing a porous layer based on oxidized cellulose,—b°) preparing a film based on chitosan starting from an acidic aqueous solution of chitosan,—c°) fixing the film obtained in b°) on one face of the porous layer,—d°) neutralizing the film obtained in b°),—where step c°) can be carried out before or after step d°), characterized in that: the neutralizing step d°) comprises treatment of said film with a neutralizing composition comprising at least ethanol and ammonium hydroxide (NH | 2015-07-23 |
20150202343 | Chronic Wound Dressing with Variable Pore Sizes - An improved skin substitute is presented comprised of a silicone layer backed up with a woven nylon fabric layer, the silicone layer possessing a regular pattern of slits that permit the porosity of the skin substitute to be adjusted by clinicians by means of applying tension to the skin substitute that differentially opens the slits. A variety of therapeutic substances can be applied to the skin substitute to promote healing, including aloe and other medicinal preparations. The skin substitute is directed at chronic wound treatment and hernia repair. | 2015-07-23 |